Alzex Neuropharma Inc.
TRRI
$0.10
-$0.02-16.67%
| 06/30/2011 | 03/31/2011 | 09/30/2010 | 06/30/2010 | ||
|---|---|---|---|---|---|
| Net Income | -68.31% | 50.26% | 81.56% | 63.85% | |
| Total Depreciation and Amortization | -5.70% | 900.00% | 8.00% | 1,092.00% | |
| Total Amortization of Deferred Charges | -- | -- | 67.70% | -- | |
| Total Other Non-Cash Items | 372.37% | 7.56% | -- | -- | |
| Change in Net Operating Assets | 261.41% | -84.98% | -128.27% | -47.38% | |
| Cash from Operations | 323.22% | -214.32% | 80.60% | 30.27% | |
| Capital Expenditure | -- | -- | -- | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -- | -- | -- | -- | |
| Total Debt Issued | -68.51% | 95.39% | -- | -31.69% | |
| Total Debt Repaid | -141.06% | -4.68% | 34.14% | -10.50% | |
| Issuance of Common Stock | -- | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | -436.20% | 380.00% | 139.60% | -59.09% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 196.38% | -77.35% | 116.07% | -233.56% | |
